Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Depreciation & Amortization (CF) (2020 - 2025)

Historic Depreciation & Amortization (CF) for Vivos Therapeutics (VVOS) over the last 6 years, with Q3 2025 value amounting to $384000.0.

  • Vivos Therapeutics' Depreciation & Amortization (CF) rose 16301.37% to $384000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 million, marking a year-over-year increase of 7252.56%. This contributed to the annual value of $581000.0 for FY2024, which is 644.12% down from last year.
  • According to the latest figures from Q3 2025, Vivos Therapeutics' Depreciation & Amortization (CF) is $384000.0, which was up 16301.37% from $306000.0 recorded in Q2 2025.
  • Vivos Therapeutics' Depreciation & Amortization (CF)'s 5-year high stood at $384000.0 during Q3 2025, with a 5-year trough of $41000.0 in Q1 2022.
  • For the 5-year period, Vivos Therapeutics' Depreciation & Amortization (CF) averaged around $182645.9, with its median value being $169000.0 (2022).
  • As far as peak fluctuations go, Vivos Therapeutics' Depreciation & Amortization (CF) tumbled by 7683.62% in 2022, and later skyrocketed by 32682.93% in 2023.
  • Quarter analysis of 5 years shows Vivos Therapeutics' Depreciation & Amortization (CF) stood at $168000.0 in 2021, then rose by 0.6% to $169000.0 in 2022, then fell by 11.83% to $149000.0 in 2023, then dropped by 3.36% to $144000.0 in 2024, then skyrocketed by 166.67% to $384000.0 in 2025.
  • Its last three reported values are $384000.0 in Q3 2025, $306000.0 for Q2 2025, and $177000.0 during Q1 2025.